IPR plays a very vital role in protecting Biotechnology transfer rights and provide the proper mechanism for the sustainable use of its components as well as the fair and equitable sharing of the benefits arising out of the use of biodiversity.
Basically, the Biotechnology defined as “any technological application,” applies to products, not procedures. In furtherance to that, the pharmaceutical industry developing immeasurably in the field of biotechnology and IPR is the only instrument which can protect the foremost rights arising out of transferring the Biotechnology.
As I mentioned earlier that technology is the application of knowledge to solving specific problems or unpretentious meeting identified needs. In respect to the aforementioned topic, biotechnology transfer appreciates as ‘the technology transfer in which the application of technologies in new geographic or product areas, generally involving adaptation to local needs and conditions.’
According to the Convention on Biological Diversity, the convention intently giving special attention and it is only because of its specific references within the Convention. Biotechnology, defined therein as “any technological application,” applies to products, not procedures. Due to the diversity of product traits, biotechnology cannot be treated as a single entity, but rather must be addressed as a composite of products with individual specific attributes and transfer processes. Technology transfer activities that are based on public-private collaborations provide a significant and distinct contribution to the economic strength and well-being of countries in which such activities take place.
The process of transfer of biotechnology enables public research institutions to obtain access to commercial research funds, state-of-the-art equipment and leading-edge technologies, while allowing industry sector to benefit from the extensive knowledge and ingenuity of academic researchers.
Apart from that, what do we mean by the biotechnology in respect of pharmaceutical?
It generally mean as pharmaceuticals manufactured by biotechnology methods, the products obviously having biological sources, usually involving the live organisms of their active components. As per my research is concerned, this view has been adopted by Biopharmaceuticals in the U.S. and European Markets.
Biopharmaceuticals is used a synonym of Pharmaceutical and in respect to that the pharmaceutical industry is now the biopharmaceutical industry. Biopharmaceuticals are no longer a subset of pharmaceuticals, with biopharmaceuticals now taking in all pharmaceutical and biotechnology companies (with a health care orientation).
Many of the research reports says that the pharmaceutical industry has just recently morphed or transformed itself into the biopharmaceutical industry as a result of the convergence of biotechnology and pharmaceutical technology; that is the pharmaceutical industry through the adoption of new technologies and close relationships with biotech companies. So because of this fundamental change, various developments happened like high-throughput screening and drug design methodologies etc.
Pharmaceutical Biotechnology is a multidisciplinary scientific field undergoing an explosive development. Advances in the understanding of molecular principles and the existence of many regulatory proteins have established biotechnological or therapeutic proteins as promising drugs in medicine and pharmacy. More recent developments in biomedical research highlight the potential of nucleic acids in gene therapy and antisense RNAi technology that may become a medical reality in the future.
Biotechnology is a fast-moving area and crucial topics for future technologies can be recognized today. We wanted to give an insight into these future enterprise technologies and had asked for contributions to highlight new developments in gene therapy, tissue engineering, personalized medicine, and xenotransplantation having a realistic chance of being used in industrial applications